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ABSTRACT 
Background   
Cryptococcus is a life-threatening opportunistic infection; data is limited regarding 
early infection. Treatment of cryptococcal antigenaemia may impact on disease 
progression. Screening those most at risk for cryptococcal antigenaemia is 
necessary to be cost effective. The prevalence of cryptococcal antigenaemia in 
patients hospitalised with community acquired pneumonia (CAP) at Chris Hani 
Baragwanath Academic Hospital (CHBAH) was evaluated. 
Methods 
200 patients admitted to CHBAH with presumed CAP were enrolled.  Clinical and 
laboratory data were collected and a Cryptococcal Lateral Flow Immunoassay was 
done on whole blood.  
Results 
Of the 200 patients, 185 (92.5%) were HIV-infected. Amongst the HIV-infected 
group, the median CD4 cell count was 47 cells/mm3 and 111 subjects (60%) had a 
CD4 cell count < 100 cells/mm3.  The prevalence of cryptococcal antigenaemia 
was 0.5% (CI 0.01-2.75).   
Conclusion 
The prevalence of cryptococcal antigenaemia amongst inpatients with CAP was 
low.  Routine screening of this group would not be cost-effective. 
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1.0 Introduction 
 
1.1 Cryptococcal disease 
The systemic mycosis cryptococcosis is a life-threatening 
opportunistic infection occurring most frequently in 
immunocompromised patients.  However, the disease has been 
described in patients with a normal immune system[1].  Among 
immunocompromised patients most of the burden falls on those 
infected with the Human Immunodeficiency Virus (HIV).  Within this 
group, the majority of affected patients have a CD4 cell count < 100 
cells/mm3[2, 3].  In a local review article other factors predisposing 
patients to cryptococcal infection were found to be: treatment with 
corticosteroids, organ transplantation and malignancies[2].  Systemic 
lupus erythematosus, sarcoidosis, chronic lung disease, sickle cell 
disease, Hepatitis B carrier state, diabetes mellitus, liver cirrhosis 
and Idiopathic CD4 lymphocytopenia have also been described as 
immunosuppressive conditions predisposing patients to cryptococcal 
infection[4-6]. 
 
In response to the demand for fast and reliable detection recent 
advances in highly sensitive and specific antigen based cryptococcal 
tests have been made[7].  Despite recent national efforts in improved 
routine laboratory based cryptococcal testing little data exists on the 
utility of cryptococcal antigen detection in the acutely ill patient[8, 9]. 
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1.1.1 Mycology of Cryptococcus 
Cryptococcus neoformans is an encapsulated yeast-like 
fungus.  Two varieties exist, namely Cryptococcus var. 
neoformans and Cryptococcus var. grubii. Cryptococcus gattii 
is now considered a distinct species.  Cryptococcus 
neoformans var. neoformans and Cryptococcus neoformans 
var. grubii have been isolated in bird excreta, especially that 
of pigeons[10]. In 1990, Ellis and Pfeiffer found the primary 
ecological source of Cryptococcus neoformans var. gattii to be 
the plant debris under the river red gum (Eucalyptus 
camaldulensis) and other native Australian trees[11]. Humans 
acquire the disease by exposure to and inhalation of the 
infectious propagules found mainly in soil and vegetation. 
These infectious propagules are hypothesized to be small 
desiccated yeast cells facilitating deposition in terminal 
bronchioles and alveoli[12, 13]. 
Cryptococcus neoformans var. neoformans, known to cause 
life-threatening disease in immunosuppressed individuals, has 
been isolated worldwide and is known to be the cause of most 
clinical cases of cryptococcosis[14, 15].  Until as recently as 10 
years ago it was thought that Cryptococcus neoformans var. 
gattii is a rare cause of fungal infection affecting mainly 
immunocompetent individuals in tropical and subtropical 
regions[16, 17].  However, in 1999 an outbreak of Cryptococcus 
var. gattii in the temperate region of British Colombia, Canada 
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showed that the infection is not limited to tropical and 
subtropical climates[18].  Cryptococcus neoformans var. gattii 
was later also found to cause disease in immunocompromised 
individuals[19]. 
 
1.1.2 Spectrum of cryptococcal disease 
The spectrum of cryptococcal infection ranges from 
asymptomatic colonization to pulmonary cryptococcosis, 
cryptococcal meningitis (CM) and severe disseminated 
disease.  Pulmonary cryptococcosis is caused by inhalation of 
the biodiospore and deposition in the terminal bronchioles and 
alveoli leading to an asymptomatic or symptomatic 
pneumonitis[15, 20].  Although pulmonary cryptococcosis is said 
to be a less common manifestation of illness, it is likely that 
the diagnosis of cryptococcosis is often missed due to the 
diagnosis of more common respiratory opportunistic infections 
and the minimal or nonspecific presenting symptoms[21]. 
 
Subsequent haematogenous spread to the central nervous 
system (CNS) causes a meningitis or meningoencephalitis. 
The lung can therefore be said to be the portal of entry for 
cryptococcal disease. 
 
 Early disease may be asymptomatic or present as an acute 
respiratory infection[22, 23].  In a retrospective, case-control 
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study by Visnegarwala et al,  29 out of 210 (13.8%) HIV-
positive patients with a positive cryptococcal antigen (CrAg) 
test had acute respiratory failure as a result of cryptococcal 
disease.  Other clinical pulmonary manifestations included 
influenza-like symptoms, cough, fever, dyspnoea, 
haemoptysis and pleural effusions.  Radiological 
manifestations included asymptomatic pulmonary nodules, 
diffuse interstitial opacities, lymphadenopathy, alveolar 
opacities, cavitary lesions and pleural effusions[21, 23]. 
 
1.1.3 Burden of cryptococcal disease 
The clinical problem is that cryptococcal testing is usually only 
performed when the patient presents with CM.  In a study of 
the current global burden of CM among patients living with 
HIV/AIDS it was estimated that of the 957 900 global cases of 
CM in 2006, 720 000 occurred in sub-Saharan Africa.  In sub-
Saharan Africa 504 000 deaths were due to CM.  There were 
an estimated 350 000 deaths due to Tuberculosis (TB) in 
2006.  This comparison clearly demonstrates the staggering 
global burden of CM[14].  CM is the most common cause of 
adult meningitis in South Africa accounting for 63% of 
microbiological diagnoses[24].  
 
Prompt identification of asymptomatic antigenaemia and early 
initiation of antifungal agents in susceptible patients may 
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therefore better outcomes by initiating appropriate treatment 
before progression to meningitis[25].  Treating disease at an 
early stage will also decrease morbidity and severe 
complications of cryptococcal disease.  
 
In a retrospective Thai study among patients hospitalised with 
pneumonia, cryptococcus was found to be the second most 
common pathogen associated with acute respiratory 
infections in HIV-infected individuals.  Of the 704 HIV-infected 
samples tested, 92 (13.1%) were CrAg positive.  53% of 
patients with a positive CrAg test had no history of CM.  43% 
of patients had a positive CrAg test and had no evidence of 
another co-infection, indicating active cryptococcal disease as 
the cause of their pneumonia.  They concluded that there is 
strong evidence for routine CrAg testing among HIV-infected 
patients hospitalised with pneumonia in Thailand and 
highlighted the need for a rapid point-of-care immunoassay in 
aiding the diagnosis of early cryptococcal disease in that 
population[26].  
 
In 2013 a Ugandan study was published looking at CrAg 
testing in HIV positive patients hospitalised at a Kampala 
hospital with an unexplained cough ≥2 weeks.  32 (5.7%) of 
the 563 HIV positive patients had a positive CrAg test.  The 
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CrAg positive patients had a median CD4 cell count of 25 
cells/mm3[27]. 
 
Cryptococcus accounts for up to 44% of annual HIV/AIDS 
deaths in sub-Saharan Africa and CM is the most common 
disease manifestation of cryptococcal infection with a global 
yearly incidence estimate of 12% among HIV-infected 
individuals[14].  In a cohort study among HIV-infected miners in 
Southern Africa assessing the cause of demise and presence 
of pulmonary disease at autopsy, cryptococcus was found in 
29 out of 202 HIV-infected individuals who died of natural 
causes.  It is therefore an important cause of death in HIV-
infected men, and in this study second only to TB[28].  
 
Taking the above-mentioned studies into account, it poses the 
question whether prognosis could be improved by 
identification and targeted pre-emptive treatment in the 
pulmonary phase of cryptococcal disease.  There is currently 
no published data looking at the prevalence of cryptococcal 
antigenaemia in patients hospitalised with community 
acquired pneumonia (CAP) in South Africa.   
  
1.1.4 Cryptococcal testing 
In the past clinicians have had to rely on microscopy and 
culture or laboratory based Cryptococcal Antigen (CrAg) 
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testing, such as the Enzyme Immunoassay (EIA) and Latex 
Agglutination (LA) for cryptococcal diagnosis.  More recently 
the Lateral Flow Immunoassay (LFA), a point-of-care test 
(POCT), was introduced as an alternative to CrAg testing.  In 
an evaluation done by Lindsley et al, the LFA was compared 
to blood cultures (the gold standard) and found to have 100% 
sensitivity when serum specimens were used.  Their 
evaluation also pointed out that the LFA complies with the 
World Health Organization’s ASSURED guidelines for POCTs 
(Affordable, Sensitive, Specific, User Friendly, Rapid, 
Equipment-free, Delivered to those who need it)[7, 29]. The LFA 
has the advantage of being an economical, highly sensitive 
and expeditious test that requires no additional laboratory 
equipment or expertise and is therefore an ideal diagnostic 
tool in a resource-limited setting. 
 
1.1.5 Cryptococcal screening 
The World Health Organisation (WHO) released their 
guideline for the Diagnosis, Prevention and Management 
of Cryptococcal Disease in HIV infected Adults, Adolescents 
and Children in Resource-limited Settings in December 2011 
[30].   In this document they recommend routine screening for 
cryptococcal disease in Antiretroviral Treatment (ART) naïve 
adults with a CD4 cell count <100 cells/mm3 prior to ART 
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initiation in populations with a high prevalence of cryptococcal 
antigenaemia. 
 
In 2013 the Southern African HIV Clinicians Society 
(SAHIVSOC) updated their Guideline for the Prevention, 
Diagnosis and Management of Cryptococcal Meningitis 
among HIV-infected Persons based on expert consensus and 
best clinical evidence[31].  In this document screening for 
cryptococcal antigenaemia is recommended for ART-naïve 
adult patients with a CD4 cell count <100 cells/mm3 who have 
no history of prior CM. 
 
Phased laboratory-based screening for cryptococcal 
antigenaemia using the LFA is currently being conducted at 
over 500 National Health Laboratories Services (NHLS) 
laboratories in Gauteng and the Free State.  All specimens 
submitted for CD4 cell count found to a CD4 cell count <100 
cells/mm3 will routinely be screened for CrAg using the LFA.  
The aim is to introduce pre-emptive antifungal treatment in all 
CrAg positive patients and thereby reduce morbidity and 
mortality associated with cryptococcal disease[9]. 
 
1.1.6 Management of cryptococcal disease 
According to the SAHIVSOC Guideline for the Prevention, 
Diagnosis and Management of Cryptococcal Meningitis, all 
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patients with a positive CrAg result should be managed as 
follows:[31] 
 Immediate evaluation for the symptoms,and signs of 
meningitis, followed by urgent cerebrospinal fluid (CSF) 
analysis for CM if no contra-indications to lumbar 
puncture (LP) exist. 
 In order to exclude early CM, CSF analysis is 
recommended in patients lacking symptoms and signs 
of meningitis if immediately attainable. 
 In patients with a CSF analysis excluding CM and 
those with no suspected meningitis, high dose oral 
Fluconazole (800mg/day) is recommended for 2 
weeks, followed by consolidation treatment (400mg/day 
for 8 weeks) and thereafter maintenance treatment 
(200mg/day until the CD4 cell count is >200 cells/mm3 
for at least 6 months and the most recent HIV viral load 
is suppressed) as recommended by the SAHIVSOC. 
 In HIV positive patients not yet on ART, it is 
recommended to commence ART 2 weeks after 
initiating antifungal therapy. 
 CrAg positive patients with a history of prior CM would 
only require full evaluation in the presence of new 
symptoms or signs of meningitis to rule out relapse 
CM.  In the absence of these symptoms and signs, 
adequate Fluconazole maintenance therapy is 
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recommended.  Following successful treatment of CM, 
the CrAg can remain positive in serum and CSF for a 
protracted period of time[32]. 
 Female patients of child-bearing age with a positive 
CrAg should have a pregnancy test.  In light of a 
negative pregnancy test the patients should be offered 
appropriate contraception and advised to avoid 
pregnancy whilst on Fluconazole.  Expert consultation 
should be sought for pregnant patients requiring 
antifungal therapy.  
 Fluconazole therapy should be continued until the CD4 
cell count is >200 cells/mm3 for at least 6 months and 
the most recent HIV viral load is suppressed. 
 Patients with CM should be treated with 2 weeks of 
induction therapy, followed by consolidation and 
maintenance antifungal therapy as per the guideline. 
 
1.1.7 Cost implications of cryptococcal disease 
In a retrospective study conducted on 707 stored plasma 
samples obtained on enrolment in an ART cohort in South 
Africa 46 (7%) were CrAg positive[33].   
 
In a Ugandan cohort 609 ART-naïve adults with AIDS 
initiating ART were prospectively enrolled to test serum CrAg.  
Of the 295 persons with CD4 cell count ≤100 cells/mm3 
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26(8.8%) were CrAg positive[34]. This cohort found the 
Number Needed to Treat (NNT) for screening was 11.3 (95% 
CI: 7.9–17.1) in those with CD4 cell count ≤100 cells/mm3 and 
15.9 (95% CI: 11.1–24.0) people would need to be screened 
and treated to prevent one death.  Despite the high cost of the 
undiluted CrAg test ($16.75 per test) in Uganda they 
concluded that CrAg screening would be cost-effective in 
persons with a CD4 cell count ≤100 cells/mm3.  If one takes 
the high cost of their CrAg testing and the potential costs of 
hospital admission into consideration, they may well be 
underestimating the actual cost-effectiveness of cryptococcal 
screening.  
 
In a cost-effectiveness analysis by Jarvis, JN et al 4 screening 
strategies for patients with CD4 cell count ≤100 cells/mm3 
starting ART were compared.  These strategies included no 
screening or prophylaxis, primary fluconazole prophylaxis, 
CrAg screening with high-dose fluconazole for CrAg positive 
patients and CrAg screening with LP in CrAg positive followed 
by amphotericin-B for those with CNS disease or fluconazole 
for those without.  The most cost-effective strategy was CrAg 
screening followed by high dose fluconazole treatment in the 
CrAg positive group.  In the group where positive CrAg 
screening was followed by LP for detection of CM the 
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additional costs of CSF analysis and amphotericin treatment 
outweighed the benefit[35]. 
 
All the above studies therefore concluded that CrAg screening 
would be a cost-effective strategy to identify individuals at risk 
for CM and to prevent CM related mortality in those patients 
initiating ART in a resource limited setting, specifically those 
with a CD4 cell count ≤100 cells/mm3.  They also state that 
ART alone is insufficient and recommend integration of CrAg 
screening and pre-emptive antifungal therapy into routine HIV 
care. 
 
1.2 Aim of the study 
The aim of the study was to determine the prevalence of 
cryptococcal antigenaemia among patients admitted to Chris Hani 
Baragwanath Academic Hospital (CHBAH) with Community Acquired 
Pneumonia (CAP) and to determine whether routine CrAg testing 
would be beneficial in patients presenting with CAP.  This strategy 
would allow screening of patients prior to obtaining their CD4 cell 
counts which may well be lower than their baseline prior to their 
acute illness. 
 
1.3 Objectives 
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a. To determine the prevalence of cryptococcal antigenaemia 
among adult patients admitted to CHBAH with Community 
Acquired Pneumonia. 
 
b. To compare CrAg positive patients with CrAg negative 
patients with regards to the following variables: age, sex, HIV 
status, respiratory rate, oxygen saturation and blood pressure. 
 
c. To do a sub-analysis of the prevalence of CrAg positivity by 
CD4 cell count stratum in the HIV positive subset of patients. 
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2.0 Materials and methods 
 
2.1 Definition of terms 
Community Acquired Pneumonia was defined as symptoms 
suggestive of a respiratory tract illness (fever, cough with or without 
sputum production, pleurisy, dyspnoea) or clinical evidence of a 
respiratory tract infection (pyrexia, tachypnoea, tachycardia, audible 
crackles) and radiological findings consistent with an acute 
respiratory infection (infiltrates on chest X-Ray)[2]. 
 
2.2 Study design 
This is a prospective, quantitative cross-sectional study with 
descriptive elements. 
 
2.3 Study setting 
The study was conducted in the medical wards at CHBAH, a level 3 
state hospital that provides healthcare services to patients across the 
Gauteng province. Consent to collect data at this facility was 
obtained from the Head of the Department of Internal Medicine, Prof 
KRL Huddle and the medical superintendent Dr KA Mustafa on 25 
January 2012. (Appendix B) 
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2.4 Study population and sample 
Cryptococcus antigen testing was performed on the first 200 patients 
admitted to the medical admissions ward at CHBAH meeting the 
inclusion and exclusion criteria. 
 
Purposive (non-random) convenience sampling using consecutive 
patients that met the inclusion criteria allowed for selection of 
individuals from the spectrum we were interested in. 
 
2.4.1 Inclusion criteria 
a. Patients aged 18 years or older; 
b. Patients who met more than two of the following clinical 
criteria as per the definition of CAP:  fever, cough, pleurisy, 
dyspnoea, crackles on chest auscultation and infiltrates on 
CXR. 
 
2.4.2 Exclusion criteria 
a. Confused patients; 
b. Patients not willing to consent to participation in the study; 
c. Patients with a history of prior cryptococcal disease; 
d. Patients currently taking fluconazole treatment. 
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2.4.3 Informed consent 
Written informed consent for access to clinical data and all 
laboratory results for research purposes was obtained from all 
participants.  The data was collected on numbered data 
sheets and an identifying code book kept by the principal 
investigator.  Access to clinical data and laboratory results 
was limited to the principal investigator who informed the 
attending physician of any positive results and the decision to 
treat patients with positive CrAg results rested upon the 
attending physician.  Attending physicians of patients with 
positive CrAg results were also advised to do a lumbar 
puncture on patients with positive CrAg results to rule out CM. 
 
2.4.4 Ethical considerations 
Ethical approval was granted by University of the 
Witwatersrand Human Research Ethics Committee. 
(Clearance number M120249; Appendix D) 
 
 
2.5 Methodology 
Adult patients admitted to the medical admissions ward at CHBAH 
with CAP were screened for inclusion into the study.  Patients were 
enrolled in the study prospectively and clinical and laboratory data 
were obtained by direct observation at the time of informed consent 
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and phlebotomy.   5ml of venous blood was collected from a 
peripheral site in an Ethylenediaminetetraacetic acid (EDTA) tube 
and tested for CrAg by the principal investigator. 
 
Cryptococcus antigen testing was performed using the Lateral Flow 
Immunoassay (Immune-mycologics, Norman, OK, USA) on blood 
collected in EDTA tubes.  All testing and data collection was done by 
the principle investigator thus avoiding interobserver bias. Test 
validation was performed as per manufacturer instruction for each 
batch of tests. 
 
All clinical information was recorded on a numbered questionnaire 
and transferred to a numbered data sheet in Microsoft Excel, Version 
14.0.6112.5000.  
 
2.5.1 Variables measured 
Age, sex, HIV status, respiratory rate, oxygen saturation and 
blood pressure were recorded from admission notes.  The 
patient’s CD4 cell count was obtained from laboratory records.  
CXR changes observed on admission CXR were also 
recorded.  Results of the LFA test were recorded. 
 
2.5.2 Sample size 
From published data, 13.1% of 704 HIV positive patients with 
respiratory symptoms were CrAg positive[18].  Using 3% CrAg 
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positivity as a cut-off for cost-effectiveness we considered 
10% to be a clinically significant difference[31]. α was set at 
0.05.  Funding was available for 200 tests.  Calculated power 
using a sample size of 200 and the above assumptions was 
0.96.  Assuming approximately 60% of patients admitted with 
respiratory symptoms in the medical wards at CHBAH are HIV 
positive we can expect approximately 120 HIV positive 
patients amongst the 200 patients entered into the study 
giving a power of 0.82. 
 
2.5.3 Comparative analysis 
I compared the proportion of positive CrAg results I obtained 
with the number of CrAg positive patients in the study 
conducted in Thailand by Harris JR et al[26]. 
 
There is currently a large surveillance study being conducted 
by the National Institute for Communicable Diseases (NICD), 
a division of the National Health Laboratory Service (NHLS).  
Monthly data is published on a provisional basis to provide 
information regarding communicable diseases.  As part of this 
surveillance the NICD’s Centre for Opportunistic, Tropical and 
Hospital Infections (COTHI) in conjunction with the 
Department of Health has begun the first phase of laboratory-
based cryptococcal antigen screening using the LFA on 
samples sent for CD4 cell count testing found to have a CD4 
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cell count of <100 cells/mm3.  In the July 2013 report it was 
stated that 7171 samples have thus far been screened, of 
which 287 (4%) tested CrAg positive[8].  I compared the 
proportion of positive CrAg results I obtained with their 
provisional CrAg results from the NICD in order to ascertain 
whether the prevalence of CrAg positivity in a population of 
patients with CAP admitted to CHBAH is similar or 
significantly different to theirs. 
 
2.6 Statistical analysis 
Data was initially collected on data collection sheets and later 
transferred to a Microsoft Office ® Excel 2010 spread sheet. Data 
was analysed using Intercooled STATA version 10 (Stata-Corp, LP, 
College Station.TX). 
 
Parametric data was described using Mean and Standard Deviation 
(SD) and non-parametric data described using Median and 
Interquartile range with a 95% Confidence Interval (CI). 
 
For comparative statistics, continuous data was analysed using the  
two-tailed unpaired t test.  Discreet data was analysed using Fisher’s 
exact test.  A P value of <0.05 was considered significant.  Non-
parametric data was analysed using the Mann-Whitney test. 
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2.7 Measurement instruments 
 
2.7.1 Lateral Flow Assay 
Cryptococcus Antigen testing was performed using the Lateral 
Flow Immunoassay (Immune-mycologics, Norman, OK, USA) 
on bloods collected in EDTA tubes.  Test validation was 
performed as per manufacturer instruction for each batch of 
tests. 
 
2.8 Limitations of the study 
Consecutive patients meeting the inclusion criteria were enrolled into 
the study, these patients were referred to the investigator by the 
admitting doctors; it is possible that referral bias existed.  Due to the 
low number of positive results I was unable to do comparative 
statistics.  Based on the literature at the time of protocol 
development the expected frequency of positive results was 
estimated to be between 10 and 15% and a 10% difference was 
considered clinically significant.  Based on these assumptions a 
sample size of 200 was determined to be adequate (α=0.05; 
power=0.96) and would have provided sufficient numbers to proceed 
with the intended comparative analyses. 
21 
 
 
 
 
 
2.9 Strengths of the study   
A complete data set was obtained with minimal missing variables. All 
tests were performed by a single operator in the field eliminating 
inter-observer variability.  The data was collected from patients with 
a wide range of age and immune status.  Amongst 
immunocompromised patients there were a sufficient number of 
patients with CD4 cell counts <100 cells/mm3.  This enabled 
comparison to a similar study by Harris JR et al and provisional data 
being collected by the NICD for the development of the new national 
cryptococcal screening guidelines[8, 26].  
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3.0 Results 
Data from two hundred patients admitted to the CHBAH medical wards with 
a diagnosis of CAP was analysed after initial screening for inclusion and 
exclusion criteria.  No subjects were excluded from the initial data 
collection. 
 
3.1 Demographics 
3.1.1 Sex and Age 
Table 3.1 indicates that the study group comprised 115 males 
(57.5%) and 85 females (42.5%). 
 
Table 3.1:  Sex of Subject in Data Set 
Sex Result 
Male 85 (42.5%) 
Female 115 (57.5%) 
Total 200 
 
Figure 3.1 illustrates the age profile of individuals in the data 
set.  The mean age of the group was 43 years (SD ± 14.4 
years).  The range was 20-79 years with an interquartile range 
(IQR) of 30 – 50.75. 
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Figure 3.1:  Age distribution of data set 
 
3.1.2 HIV status 
Of the 200 subjects included in the data set 185 were HIV 
positive, 13 HIV negative and 2 patients weren’t aware of their 
current HIV status as illustrated in Table 3.2. 
 
Table 3.2:  HIV Status of Subjects in Data Set 
HIV Status Result 
HIV Positive 185 (92.5%) 
HIV Negative 13 (6.5%) 
Unknown 2 (1%) 
Total 200 
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3.1.3 CD4 cell count stratification and  Antiretroviral therapy 
Among the HIV positive subjects, the median CD4 cell count 
was 47 cells/mm3 (range:0-1439 cells/mm3, IQR20.75 – 
170.75 cells/mm3).  111 (60%) of 185 HIV positive patients 
had a CD4 cell count of <100 cells/mm3.   
137 (74.05%) had a CD4 cell count of ≤200 cells/mm3 and 156 
(84.32%) had a CD4 cell count of ≤350 cells/mm3.  49 (26.5%) 
were on ART.  Based on the new national ART guidelines 
implemented by the Department of Health on 1 April 2013, 
156 (84.32%) subjects were eligible for ART[36].  137 (74.05%) 
subjects were eligible for ART based on the former ART 
guidelines[37]. 
 
 
 
Table 3.3: CD4 cell count Stratification of HIV positive subjects 
CD4 cell count (cells/mm3) Result 
<100 111 (60%) 
101-200 26 (14%) 
201-350 19 (10%) 
>350 16 (8%) 
Unknown 13 (8%) 
Mean 128.5 
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IQR 20.75 - 170.75 
Median 47 
 
 
 
 
 
Figure 3.2: CD4 cell count distribution 
 
 
Figure 3.3: Comparison of subjects eligible for ART based on 
old and new guidelines vs. patients currently on ART 
0
20
40
60
80
100
120
No of HIV +ve Subjects
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
90,00%
CD4 <200 CD4 < 350
On ART
Eligible for ART
26 
 
 
 
3.1.4 Smoking habits 
Of the 200 subjects in the study group, 32 (16%) were 
smokers, 16 (8%) were ex-smokers and 152 (76%) were non-
smokers.  Of the 185 HIV positive patients, 24 (12.9%) were 
current smokers and 15 (8.1%) were ex-smokers. 
 
3.1.5 Tuberculosis history 
Table 3.4 illustrates the TB history within our cohort. 
 
Table 3.4: Tuberculosis history of subjects in data set 
TB History Result 
Current TB 41 (20.5%) 
Previous TB 38 (19%) 
No history of TB 121 (60.5%) 
Total 200 
 
 
3.1.6 LFA Results 
Of the 200 patients tested for LFA only 1 tested positive giving 
a prevalence of 0.5% (CI 0.01 – 2.75%); This one patient was 
HIV positive and had a CD4 cell  count < 100cells/mm3.  When 
excluding patients with CD4 cell counts above 100 cells/mm3 
there was a 0.9% prevalence (CI 0.02 -4.92%). 
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My data did not allow for statistical comparison between CrAg 
positive and CrAg negative patients within my sample owing 
to the low rate of CrAg positivity in the sample population. 
 
As my number of positive patients was less than 5, I was 
unable to perform standard parametric testing for differences 
of proportions between my sample and those of Harris JR et 
al and the provisional figures reported by the NICD, therefore 
an exact test was required and the limitations of the statistical 
test in this situation is recognised[8, 26]. 
 
Differences in prevalence between the sample populations 
were tested using the Fisher’s exact test and were found to be 
significantly different as illustrated in Tables 3.5 and 3.6. 
 
Table 3.5: 2x2 table for the LFA positive and LFA negative 
patients in my study and the NICD provisional figures  
 My study NICD figures Total 
LFA positive 1 287 288 
LFA negative 199 6884 7083 
Total 200 7171 7371 
  
The two-tailed Fisher’s exact P value equals 0.0049.  
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Table 3.6: 2x2 table for LFA positive and LFA negative 
patients in my study and results found by Harris JR et al 
 My study Harris JR et 
al 
Total 
LFA positive 1 92 93 
LFA negative 199 704 903 
Total 200 796 996 
The two-tailed Fisher’s exact P value equals 0.0001.  
When comparing only patients with a CD4 cell count < 100 
cells/mm3 from my sample with the NICD provisional data (all 
patients in subset had a CD4 cell count < 100 cells/mm3) no 
significant difference was found as illustrated in Table 3.7.  
CD4 cell count data was not available from the Harris study. 
 
Table 3.7: 2x2 table for LFA positive and LFA negative 
patients with CD4<100 cells/mm3 in my study and the NICD 
provisional figures 
 My study NICD figures Total 
LFA positive & 
CD4<100 cells/mm3 
1 287 288 
LFA negative & 
CD4<100 cells/mm3 
110 6884 6994 
Total 111 7171 7282 
The two-tailed P value equals 0.1340. 
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4.0 Discussion 
 
With regards to the demographic profile of my sample there was a female 
predominance and the majority of patients were younger than 40 years of 
age. This is in keeping with the profile of the HIV epidemic in Sub-Saharan 
Africa[38].   
 
In this non-randomised sample of consecutive patients presenting with CAP 
92.5% were HIV-infected which was above our estimate of 60%.  Reasons 
for the high proportion of HIV-infected patients may include potential referral 
bias as ward staff may have preferentially referred HIV-infected patients for 
inclusion in my CrAg study.  CHBAH is a tertiary hospital and due to bed 
shortages only the sickest patients are admitted which may have increased 
proportions of patients with advanced HIV disease. 
 
The median CD4 cell count was 47cells/mm3.  However, patients were 
acutely ill and the CD4 cell count prior to acute illness was likely higher.  In 
patients with acute bacteraemic streptococcal CAP the difference between 
median CD4 cell count at presentation and 1 month post resolution was 158 
cells/mm3[39].  Even when this acute decrease in CD4 cell count is taken into 
account the majority of my cohort would still be severely 
immunocompromised and would still have been eligible for ART prior to 
their admission to hospital. 
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The very low number of eligible patients on ART 9 years post ART roll-out 
in the public sector is of concern.  Despite best efforts to increase access to 
ART in South Africa 8-26% of patients die within the first year of ART 
initiation largely due to very low CD4 cell counts and advanced symptomatic 
disease[40].  The addition of routine cryptococcal screening to the national 
program may cause additional strain on a system that appears to be failing.  
Perhaps more emphasis should be placed on early identification of HIV 
infection within the population and timeous initiation of ART. 
 
A fifth of patients in my study were on TB treatment at the time of data 
collection.  A similar number of patients had a history of prior TB.  This 
reflects the high burden of tuberculosis in our community.   
 
I report a prevalence of cryptococcal antigenaemia of 0.5% amongst 
patients presenting to the CHBAH medical wards with a diagnosis of CAP.  
This was significantly lower than previous studies looking at cryptococcal 
antigenaemia in patients presenting with respiratory symptoms[26, 27].  This 
result was surprising given the high percentage of HIV infected patients with 
CD4<100cells/mm3 in my study.  This difference in the prevalence of 
cryptococcal antigenaemia may be due to: 
 Possible genetic susceptibility to cryptococcal infection (although 
different genetic susceptibility to infection has not been 
described, a recent study has shown polymorphisms of 
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phagocytic Fc gamma receptors as potential markers of 
increased risk for cryptococcal disease)[41]. 
 Geographic variation may play a role in the prevalence of 
cryptococcus in the environment.  Despite the Red Eucalyptus 
being endemic on the Highveld, the cold, dry winters and high 
altitude may result in a lower number of environmental sources 
[11, 16-18]. 
 A high burden of other respiratory opportunistic infections (e.g. 
Tuberculosis) may result in underrepresentation of the less 
pathogenic Cryptococcus in this population. 
 Cryptococcal respiratory disease usually presents with no or 
minimal symptoms not requiring tertiary inpatient management 
and a higher prevalence may be found in patients with less 
severe illness.  However, the study by Visnegarwala et al showed 
that a high percentage of respiratory failure in their cohort was 
due to cryptococcal disease suggesting that severe respiratory 
illness does not exclude a diagnosis of cryptococcal disease[25]. 
 CD4 count at the time of acute respiratory illness is not 
necessarily representative of the patient’s true immune status as 
demonstrated by Schleicher GK et al[39]. 
 
Owing to the low prevalence of cryptococcal antigenaemia in my study I 
was unable to do comparative analysis between CrAg positive and 
negative patients or CD4 count stratification. 
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The prevalence of cryptococcal antigenaemia detected in my study in 
patients with CAP independent of CD4 count was low and the 95% CI 
(0.01 – 2.75%) did not  cross the proposed cut-off of 3% for cost-
effectiveness of cryptococcal screening.  When looking at only those 
patients with CD4<100cells/mm3 the 95% CI (0.02 -4.92%) did cross the 
proposed threshold of 3%.  My study does not support the findings of 
previous researchers that used respiratory symptoms as a screening 
tool for cryptococcal antigenaemia in other resource-limited settings[26]. 
However, even with the low prevalence of cryptococcal antigenaemia 
found in this population CrAg screening in patients with 
CD4<100cells/mm3 would still be cost-effective.  The cost-benefit 
analysis was a conservative calculation and savings from reduced 
inpatient management and avoidance of further expensive antifungal 
treatment would add to the cost-effectiveness.  Furthermore, decreased 
cost per unit due to increased scale would further enhance cost-
effectiveness.  Therefore, routine CrAg screening should be performed 
in this subgroup.  
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5.0 Conclusion 
 
Cryptococcal disease accounts for the majority of deaths among HIV-
infected patients in the developing world[14]. 
 
 
In patients admitted to CHBAH with CAP during June-July 2013 a 
prevalence of cryptococcal antigenaemia of 0.5% was found.  This 
prevalence was lower than expected given prior results from similar studies.   
 
Screening all patients admitted with CAP at CHBAH independent of HIV 
status and CD4 count would not be cost-effective.  However, when limited to 
patients with CD4 cell counts < 100cells/mm3 CrAg screening would be cost-
effective, especially considering availability of the recently developed highly 
sensitive and specific LFA.   
 
In conclusion, I therefore advocate the use of CrAg screening in AIDS 
patients presenting with respiratory symptoms and a CD4 cell counts < 
100cells/mm3.  Given the high prevalence of untreated advanced HIV 
disease in this subset improved early diagnosis of HIV infection and 
timeous ART initiation should be a priority.   
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5.1 Recommendations 
This is the only study to date looking at cryptococcal antigen testing 
in patients admitted with CAP in South Africa.  More studies are 
needed to confirm or refute my findings.  Although cryptococcal 
infection is not common amongst the general population, it is one of 
the most devastating opportunistic infections in immunocompromised 
individuals.  Challenges remain and more work is required to 
determine the true burden of cryptococcal respiratory disease, 
especially amongst immunocompromised patients in our community. 
 
I recommend a larger sample size in future studies given the low 
prevalence of cryptococcal antigenaemia found in this population. 
Further studies including patients with acute respiratory infections 
not requiring tertiary care is recommended for earlier recognition of 
cryptococcal antigenaemia. 
 
The large number of HIV positive patients eligible for ART but not yet 
on ART suggests that more focus be placed on early diagnosis and 
treatment initiation. 
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